Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 1.00 |
| ▸ | MYC | P01106 | 1/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 1/20 | 1.00 |
| ▸ | MAP2K3 | P46734 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24233324 | 0.93 | SOAT2 (0.87) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7573425 | 0.90 | SOAT2 (0.81) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7567657 | 0.89 | SOAT2 (0.79) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7612729 | 0.88 | SOAT2 (0.79) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7567505 | 0.88 | SOAT2 (0.78) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7572791 | 0.88 | SOAT2 (0.78) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7570156 | 0.87 | SOAT2 (0.77) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7565721 | 0.87 | SOAT2 (0.77) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7566055 | 0.87 | SOAT2 (0.77) | SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL7574340 | 0.87 | SOAT2 (0.77) | SOAT2MYCSOAT1MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10722 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| WO-2025226325-A2 | IN VITRO SYSTEMS FOR GENERATION OF SKIN EQUIVALENTS AND USES THEREOF AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONNECTIVE TISSUE DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-30 | — | — | WO | claimed |
| EP-3787631-B1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR NASH AND OTHER METABOLIC DISORDERS | UNIV EMORY (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250255829-A1 | Multifunctional Nanoparticles and Uses in Managing Cancer and Cardiovascular Diseases | UNIV EMORY (US) | 2025-08-14 | — | — | US | claimed |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-20 | — | — | US | claimed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | claimed |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | PURDUE RESEARCH FOUNDATION (US) | 2025-03-25 | — | — | US | claimed |
| WO-2001074835-A1 | O-GLUCOSYLATED BENZAMIDE SGLT2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-11 | — | — | WO | claimed |
| WO-2001068603-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL-MYERS SQUIBB CO. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001060807-A1 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO. INC. (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001056556-A2 | DUAL INHIBITORS OF CHOLESTERYL ESTER AND WAX ESTER SYNTHESIS FOR SEBACEOUS GLAND DISORDERS | WARNER-LAMBERT COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2001021602-A1 | OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |